Nurix Therapeutics, Inc.: Form 10-Q for the period ended Aug 31, 2021
Filed with the SEC on Oct 14, 2021 and accepted by EDGAR at Oct 14, 2021, 16:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-06-01 to 2021-08-31 | $10.3m | us-gaap:Revenues |
| Revenue | 9 months2020-12-01 to 2021-08-31 | $22.4m | us-gaap:Revenues |
| Research and development | 3 months2021-06-01 to 2021-08-31 | $30.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-12-01 to 2021-08-31 | $79.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-06-01 to 2021-08-31 | −$29.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-12-01 to 2021-08-31 | −$79.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-06-01 to 2021-08-31 | −$123.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-12-01 to 2021-08-31 | $87.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-06-01 to 2021-08-31 | −$28.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-12-01 to 2021-08-31 | −$79.5m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2020-12-01 to 2021-08-31 | −$53.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-12-01 to 2021-08-31 | $4.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-08-31 | $147.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-08-31 | $358.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-08-31 | $493.1m | us-gaap:Assets |
| Current liabilities | At period end2021-08-31 | $50.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-08-31 | $117.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-08-31 | $375.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-21-050851. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.